Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.

E L SimpsonJ-P LacourLynda SpelmanR GalimbertiL F EichenfieldRobert BissonnetteB A KingJ P ThyssenJonathan Ian SilverbergT BieberK KabashimaY TsunemiA CostanzoEmma Guttman-YasskyL A BeckJ M JanesA M DeLozierM GamaloD R BrinkerT CardilloF P NunesA S PallerA WollenbergK Reich

Published in: The British journal of dermatology (2020)

Baricitinib improved clinical signs and symptoms in patients with moderate-to-severe AD within 16 weeks of treatment and induced rapid reduction of itch. The safety profile remained consistent with prior findings from baricitinib clinical development in AD, with no new safety concerns.

Keyphrases

phase iii
open label
atopic dermatitis
double blind
clinical trial
placebo controlled
phase ii
early onset
drug induced
high intensity
combination therapy
high glucose
randomized controlled trial
endothelial cells